

Sun Pharmaceutical Industries Ltd.

Tandalja, Vadodara - 390 012, INDIA.

Tel. : 91-265-6615500/6615600/6615700

Fax : 91-265-2354897

CIN : L24230GJ1993PLC019050



**June 04, 2019**

**National Stock Exchange of India Limited**

Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai – 400 051

**NSE Code: SUNPHARMA**

**BSE Limited**

Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001

**Stock Code: 524715**

**Sub: Proceedings of National Company Law Tribunal (“NCLT”) convened separate meetings of the equity shareholders and unsecured creditors of Sun Pharmaceutical Industries Limited (“the Company”) held today, June 04, 2019**

Dear Sirs,

Pursuant to the order dated April 11, 2019, passed by the Hon’ble NCLT, Ahmedabad Bench, the separate meetings of equity shareholders and unsecured creditors of the Company were held at Prof. Chandravadan C. Mehta Auditorium – General Education Centre, Maharaja Sayajirao University of Baroda, Near D. N. Hall, Pratap Gunj, Vadodara-390 002, Gujarat, India on Tuesday, June 04, 2019 at 10:15 a.m. and 11:15 a.m. IST respectively, for approving the Composite Scheme of Arrangement among Sun Pharmaceutical Industries Limited and Sun Pharma (Netherlands) B.V. (“Transferee Company-1”) and Sun Pharmaceutical Holdings USA Inc. (“Transferee Company-2”) and their respective members and creditors (“Scheme of Arrangement”) for transfer of the Specified Investment Undertaking-1 (as defined in Scheme of Arrangement) and Specified Investment Undertaking-2 (as defined in Scheme of Arrangement) of the Company into Transferee Company -1 and Transferee Company-2 respectively.

Mr. Gaurang Parikh, Chartered Accountant, an Independent Professional, the Chairman of the meetings as appointed by Hon’ble NCLT, chaired the meetings. Mr. Gautam Doshi and Mr. Sailesh T. Desai, the Directors of the Company attended the Meeting. The other Directors of the Company could not attend the Meeting due to their prior commitments and/or occupancy with urgent work. The requisite quorum was present at the meetings. The Chairman inter alia explained the implications, benefits and objectives of the Composite Scheme of Arrangement. The electronic voting process was conducted at the equity shareholders’ meeting and poll was conducted at the unsecured creditors’ meeting. Mr. C. J. Goswami, proprietor of M/s. C. J. Goswami and Associates, Practicing Company Secretaries, Mumbai, appointed by Hon’ble NCLT, was the Scrutinizer for the remote e-voting and electronic voting process at the venue of the meeting for equity shareholders’ meeting and for poll at the venue of the meeting for the unsecured creditors’ meeting.

In case of equity shareholders’ meeting, in compliance with Hon’ble NCLT Order, with the provisions of Section 230(4) read with Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other

Sun Pharmaceutical Industries Ltd.

Tandalja, Vadodara - 390 012, INDIA.

Tel. : 91-265-6615500/6615600/6615700

Fax : 91-265-2354897

CIN : L24230GJ1993PLC019050



applicable regulations, the Company had provided the facility to the equity shareholders of the Company to cast their votes either by way of remote e-voting facility during the period commencing from Saturday, June 01, 2019 at 9:00 a.m. IST and ending on Monday, June 03, 2019 at 5:00 p.m. IST (inclusive of both the days) or an electronic voting process which was conducted at the meeting.

In case of unsecured creditors' meeting, in compliance with NCLT Order, voting through poll at the venue of the meeting was carried out.

We would like to inform you that the resolution for the approval of Composite Scheme of Arrangement is approved by the equity shareholders by requisite majority and by unsecured creditors of the Company unanimously.

As per the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the detailed results of voting for the resolution proposed at the meeting of the equity shareholders will be intimated separately.

We request you to kindly take note of the same.

Thanking You,

Yours faithfully,

For **Sun Pharmaceutical Industries Limited**

A handwritten signature in blue ink, appearing to read "A I Bhuta".

**Ashok I. Bhuta**  
**Sr. GM - Secretarial &**  
**Compliance Officer**